IRIS
CAMELI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 12.920
NA - Nord America 11.608
AS - Asia 5.951
SA - Sud America 1.216
AF - Africa 177
OC - Oceania 33
Continente sconosciuto - Info sul continente non disponibili 6
AN - Antartide 1
Totale 31.912
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.379
RU - Federazione Russa 3.286
IT - Italia 2.977
SG - Singapore 2.186
GB - Regno Unito 1.731
IE - Irlanda 1.650
CN - Cina 1.606
BR - Brasile 1.042
DE - Germania 787
SE - Svezia 738
HK - Hong Kong 641
FR - Francia 468
FI - Finlandia 444
VN - Vietnam 378
KR - Corea 299
IN - India 293
UA - Ucraina 187
ES - Italia 138
NL - Olanda 133
CA - Canada 120
JP - Giappone 86
PL - Polonia 80
MX - Messico 77
CZ - Repubblica Ceca 76
BD - Bangladesh 68
CI - Costa d'Avorio 60
AT - Austria 53
ZA - Sudafrica 53
TR - Turchia 48
AR - Argentina 46
IQ - Iraq 42
EC - Ecuador 40
IR - Iran 40
PK - Pakistan 36
CH - Svizzera 24
AU - Australia 23
AE - Emirati Arabi Uniti 22
ID - Indonesia 22
SA - Arabia Saudita 22
MA - Marocco 21
BE - Belgio 20
LT - Lituania 20
PH - Filippine 19
UZ - Uzbekistan 19
VE - Venezuela 17
CL - Cile 15
CO - Colombia 14
PE - Perù 14
PY - Paraguay 14
AZ - Azerbaigian 13
EG - Egitto 11
IL - Israele 11
KZ - Kazakistan 11
PT - Portogallo 11
DK - Danimarca 10
HU - Ungheria 10
JO - Giordania 10
RO - Romania 10
BG - Bulgaria 9
JM - Giamaica 9
KG - Kirghizistan 9
GE - Georgia 8
KE - Kenya 8
NZ - Nuova Zelanda 8
EE - Estonia 7
LB - Libano 7
MK - Macedonia 7
NG - Nigeria 7
AL - Albania 6
BO - Bolivia 6
EU - Europa 6
LA - Repubblica Popolare Democratica del Laos 6
LK - Sri Lanka 6
LV - Lettonia 6
MY - Malesia 6
PA - Panama 6
UY - Uruguay 6
RS - Serbia 5
TH - Thailandia 5
TN - Tunisia 5
AM - Armenia 4
CR - Costa Rica 4
CY - Cipro 4
DZ - Algeria 4
GR - Grecia 4
LU - Lussemburgo 4
NP - Nepal 4
OM - Oman 4
BY - Bielorussia 3
DO - Repubblica Dominicana 3
HR - Croazia 3
IS - Islanda 3
KW - Kuwait 3
NO - Norvegia 3
SN - Senegal 3
TT - Trinidad e Tobago 3
BB - Barbados 2
BH - Bahrain 2
ET - Etiopia 2
MD - Moldavia 2
Totale 31.883
Salva come PNG Salva come JPEG
Città #
Dallas 2.885
Dublin 1.620
Southend 1.442
Singapore 1.402
Moscow 991
Ashburn 910
Santa Clara 872
Fairfield 730
Chandler 715
Hong Kong 623
Siena 494
Beijing 471
Hefei 374
Munich 368
Woodbridge 321
Milan 319
Lastra a Signa 314
Wilmington 306
Houston 298
Helsinki 280
Seoul 279
Seattle 267
Los Angeles 260
New York 238
Princeton 230
Cambridge 228
Florence 220
Ann Arbor 146
Rome 127
Ho Chi Minh City 108
São Paulo 107
Jacksonville 106
Shanghai 94
Chicago 87
Redondo Beach 84
Bengaluru 82
San Mateo 76
Turku 76
Dong Ket 75
Buffalo 73
Fremont 70
Warsaw 69
Lappeenranta 68
Málaga 68
San Diego 65
Tokyo 64
Abidjan 60
Nuremberg 60
Boardman 59
Düsseldorf 59
Hanoi 59
Lauterbourg 58
London 58
The Dalles 56
Portsmouth 52
Dearborn 51
Stockholm 45
Brno 44
Brooklyn 41
Council Bluffs 40
Rio de Janeiro 39
Phoenix 38
Montreal 37
Atlanta 36
Frankfurt am Main 35
Johannesburg 35
Washington 35
Chennai 34
Toronto 32
Denver 31
Boston 29
Brescia 29
Guangzhou 29
Vienna 27
Dhaka 26
Gavirate 26
Manchester 26
Poplar 26
San Francisco 26
Olomouc 24
Padova 24
Naples 23
Orem 23
Brasília 22
Mexico City 22
Hyderabad 21
Salt Lake City 21
Newark 20
Belo Horizonte 19
Brussels 19
Gießen 19
Agliana 18
Nanjing 18
Querétaro 18
Ankara 17
Bologna 17
Changsha 17
Curitiba 17
Tarazona 17
Zhengzhou 17
Totale 20.853
Salva come PNG Salva come JPEG
Nome #
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 545
A first update on mapping the human genetic architecture of COVID-19 539
A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of death 459
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 455
Genetic mechanisms of critical illness in COVID-19 332
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 328
An explainable model of host genetic interactions linked to COVID-19 severity 324
Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis 317
Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis 309
Peripheral biomarkers' panel for severe COVID-19 patients 291
Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research 286
Pathogen-sugar interactions revealed by universal saturation transfer analysis 269
Mapping the human genetic architecture of COVID-19 262
Antithrombin III as predictive indicator of survival in IPF patients treated with Nintedanib: a preliminary study 260
Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6 259
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity 258
Long Covid: analisi di casistica in follow-up a seguito di successive ondate epidemiche 255
Exhaled nitric oxide in interstitial lung diseases 252
ACUTE HF score, a multiparametric prognostic tool for acute heart failure: A real-life study 250
Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib 246
Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males 245
Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease 240
The effect of cigarette smoking on bronchoalveolar lavage protein profiles from patients with different interstitial lung diseases 238
Adiponectin and leptin levels in idiopathic pulmonary fibrosis: A new method for BAL and serum assessment 232
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 232
A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting 227
Pleuroparenchymal fibroelastosis (PPFE) associated with giant cell arteritis: A coincidence or a novel phenotype? 226
Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19 225
Omalizumab treatment in Samter's triad: case series and review of the literature 225
Serum amyloid A in patients with idiopathic pulmonary fibrosis 221
Prognostic bioindicators in severe COVID-19 patients 217
SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic variants affecting gene expression in a variety of tissues 216
Alveolar nitric oxide is related to periostin levels in idiopathic pulmonary fibrosis 215
Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab 214
Adaptive immune system in pulmonary sarcoidosis - comparison of peripheral and alveolar biomarkers 214
COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs 213
Serial KL-6 measurements in COVID-19 patients 212
AB0611 Neutrophil extracellular traps and interstitial lung disease in ANCA-associated vasculitis: a scoping review 209
Incremental value of pocket-sized imaging device for bedside diagnosis of unilateral pleural effusions and ultrasound-guided thoracentesis 208
BAL biomarkers’ panel for differential diagnosis of interstitial lung diseases 204
A real-life experience with ImmunoCAP ISAC: the advantages of a new diagnostic method 204
Severe COVID-19 in hospitalized carriers of single CFTR pathogenic variants 204
NK and NKT-like cells in granulomatous and fibrotic lung diseases 203
Comparison of Right Versus Left Ventricular Strain Analysis as a Predictor of Outcome in Patients With Systolic Heart Failure Referred for Heart Transplantation 202
Alveolar nitric oxide as a biomarker of COVID-19 lung sequelae: A pivotal study 202
Serum KL-6 concentrations as a novel biomarker of severe COVID-19 201
Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features 200
Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes 197
BAL and serum multiplex lipid profiling in idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis 195
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena 193
Regulatory T Cells in Severe Persistent Asthma in the Era of Monoclonal Antibodies Target Therapies 191
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 191
Serum amyloid A: A potential biomarker of lung disorders 189
Serum concentrations of Krebs von den Lungen-6 in different COVID-19 phenotypes 188
A multicenter approach to evaluate omalizumab effectiveness in Samter’s triad 186
The impact of antifibrotic therapy in the management of idiopathic pulmonary fibrosis and progressive fibrosing interstitial lung diseases: a real-world comparative study of efficacy between pirfenidone and nintedanib 185
Immune-Checkpoint Expression on CD4, CD8 and NK Cells in Blood, Bronchoalveolar Lavage and Lymph Nodes of Sarcoidosis 184
Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II 184
Portable Pocket-Sized Ultrasound Scanner for the Evaluation of Lung Involvement in Coronavirus Disease 2019 Patients 183
WES profiling of COVID-19 183
Traditional and Novel Imaging of Right Ventricular Function in Patients with Heart Failure and Reduced Ejection Fraction 182
Efficacy of baricitinib in treating rheumatoid arthritis: Modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting 181
Altered serum concentrations of IL-8, IL-32 and IL-10 in patients with lung impairment 6 months after COVID-19 176
Basic and advanced echocardiography in advanced heart failure: an overview 176
BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures 175
Effects of rituximab therapy on B cell differentiation and depletion 175
Idiopathic Pulmonary Fibrosis Serum proteomic analysis before and after nintedanib therapy 174
Peripheral and alveolar biomarkers of fibrotic hypersensitivity pneumonitis 173
Cor pulmonale: the role of traditional and advanced echocardiography in the acute and chronic settings 172
The Role of Urinary Calcium and Chitotriosidase in a Cohort of Chronic Sarcoidosis Patients 168
Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab 168
Ultra-rare RTEL1 gene variants associate with acute severity of COVID-19 and evolution to pulmonary fibrosis as a specific long COVID disorder 167
Right cardiac involvement in lung diseases: a multimodality approach from diagnosis to prognostication 167
Clinical and molecular characterization of COVID-19 hospitalized patients 166
Left atrial strain as a pre-operative prognostic marker for patients with severe mitral regurgitation 165
Krebs von den Lungen-6 as biomarker for disease severity assessment in interstitial lung disease: a comprehensive review 164
Serum CD59: a novel biomarker of idiopathic pulmonary fibrosis? 160
Severe asthma and long-term Benralizumab effectiveness in real-life 159
Systematic review and metanalysis of oncomarkers in ipf patients and serial changes of oncomarkers in a prospective italian real-life case series 159
Peripheral lymphocyte subset monitoring in COVID-19 Italian patients 158
Prognostic role of KL-6 in lymphangioleiomyomatosis patients 157
Immunologic responses to antifibrotic treatment in IPF patients 153
Protective role of a TMPRSS2 variant on severe COVID-19 outcome in young males and elderly women 153
Common molecular pathways targeted by nintedanib in cancer and IPF: a bioinformatic study 152
Proteomic characterization of idiopathic pulmonary fibrosis patients: stable versus acute exacerbation 151
Collagen Type IV Alpha 5 Chain in Bronchiolitis Obliterans Syndrome After Lung Transplant: The First Evidence 150
Differential redox proteomic profiles of serum from severe asthma patients after one month of Benralizumab and Mepolizumab treatment 149
Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment 149
The Effects of Interstitial Lung Diseases on Alveolar Extracellular Vesicles Profile: A Multicenter Study 148
Timing of Osteoporotic Vertebral Fractures in Lung and Heart Transplantation: A Longitudinal Study 147
Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study 146
Utility of serological biomarker' panels for diagnostic accuracy of interstitial lung diseases 146
CD103 Expression on Regulatory and Follicular T Cells in Lymph Nodes, Bronchoalveolar Lavage Fluid and Peripheral Blood of Sarcoidosis Patients 144
Whole-genome sequencing reveals host factors underlying critical COVID-19 143
Serial investigation of Angiotensin-Converting Enzyme in sarcoidosis patients treated with Angiotensin-Converting Enzyme Inhibitor 143
Biomarkers predict in-hospital major adverse cardiac events in covid-19 patients: A multicenter international study 143
Cytological analysis of bronchoalveolar lavage fluid in asbestos-exposed workers: BALF features in asbestos exposed workers 142
Echocardiography for left ventricular assist device implantation and evaluation: an indispensable tool 140
Bone fragility and sarcoidosis: An underestimated relationship 139
Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis 137
Totale 21.111
Salva come PNG Salva come JPEG
Categoria #
all - tutte 116.069
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 116.069
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.759 0 0 0 0 0 298 211 344 265 174 239 228
2021/20222.553 187 281 225 182 124 114 110 118 114 321 269 508
2022/20233.028 200 342 390 305 186 521 261 265 210 123 127 98
2023/20243.392 132 93 328 173 170 737 956 193 56 119 127 308
2024/20257.932 607 312 846 453 960 485 452 458 644 394 729 1.592
2025/202611.694 1.279 2.445 2.254 2.176 3.399 141 0 0 0 0 0 0
Totale 32.840